Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer

Seminars in Oncology · Published 2026-04-12 · DOI 10.1016/j.seminoncol.2026.152499

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.seminoncol.2026.152499

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Antibody treatments for digestive cancers: Past, present, and future · Seminars in Oncology · 2025 · Same journal
• Genetic and systems-level regulation of cancer metabolism: From metabolic reprogramming to AI-driven precision oncology · Seminars in Oncology · 2026 · Same journal
• The role of circular RNAs in driving cancer advancement in low-oxygen conditions · Seminars in Oncology · 2025 · Same journal
• A bibliometric analysis of research evolution on peritoneal metastasis in colorectal cancer (2000–2026): advances in molecular mechanisms and therapeutic strategies · Seminars in Oncology · 2026 · Same journal
• PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation · Seminars in Oncology · 2026 · Same journal
• Immuno-oncology approaches to overcome T cell exhaustion in melanoma · Seminars in Oncology · 2025 · Same journal
• Artificial intelligence in gynecologic oncology: A cautionary look in the Indian context · Seminars in Oncology · 2025 · Same journal
• Prognostic significance and therapeutic potential of pyroptosis in gynecological malignancies · Seminars in Oncology · 2026 · Same journal
• Pregnancy during pembrolizumab therapy for triple-negative breast cancer with onset of congenital hypothyroidism: Case report, literature review, and caution for clinical practice · Seminars in Oncology · 2026 · Same journal
• Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer · Seminars in Oncology · 2025 · Same journal